Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.

Autor:	Sessa B; Centre for Neuropsychopharmacology, Imperial College London, London, UK., Aday JS; Department of Psychology, Central Michigan University, Mount Pleasant, MI, USA.; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA.; DrugScience, London, UK., O'Brien S; Centre for Neuropsychopharmacology, Imperial College London, London, UK., Curran HV; Research Department of Clinical, Educational & Health Psychology, University College London, London, UK.; National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK., Measham F; Department of Sociology, Social Policy and Criminology, University of Liverpool, Liverpool, UK., Higbed L; Centre for Neuropsychopharmacology, Imperial College London, London, UK., Nutt DJ; Centre for Neuropsychopharmacology, Imperial College London, London, UK.; DrugScience, London, UK.
Jazyk:	angličtina
Zdroj:	Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2022 Mar; Vol. 36 (3), pp. 360-367. Date of Electronic Publication: 2021 Dec 13.
DOI:	10.1177/02698811211055809
Abstrakt:	Background: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as 'Blue Mondays', have been raised as limitations to its clinical use. Although these changes have been well-documented among recreational users, there are critical confounds to these reports that limit generalizability to clinically administered MDMA. Aims: Here, we aimed to evaluate the evidence basis for the negative side effects associated with MDMA as well as inform our understanding of the drug's post-acute effects in a clinical context with an open-label study. Methods: The current open-label study examined MDMA therapy for alcohol use disorder (AUD; N = 14) and measured mood, sleep quality, illicit MDMA consumption and anecdotal reports after the acute drug effects had worn off. Results: Participants maintained a positive mood during the week following drug administration in a clinical context. Relative to baseline, self-reported sleep quality improved at the 3- and 6-month follow-ups. Finally, no participants reported using or desiring to use illicit MDMA, and the anecdotal reports indicated that they perceived the treatment favourably. Conclusion: The results support the overall safety and tolerability of clinically administered MDMA and, importantly, suggest that the 'come downs' previously associated with the substance may be explained by confounds in research relating to the illicit sourcing of the drug and specific environmental setting for recreational consumption.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu